这篇文章不错，转发给_老虎社区_美港股上老虎

2023-02-03

这篇文章不错，转发给大家看看

Why Editas Medicine Stock Charged Higher in January

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":622884289,"tweetId":"622884289","gmtCreate":1675374479842,"gmtModify":1675374899693,"author":{"id":4103107643759280,"idStr":"4103107643759280","authorId":4103107643759280,"authorIdStr":"4103107643759280","name":"heming","avatar":"https://static.tigerbbs.com/21537935b4fa6c2ac25a53139959150d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>这篇文章不错，转发给大家看看</body></html>","htmlText":"<html><head></head><body>这篇文章不错，转发给大家看看</body></html>","text":"这篇文章不错，转发给大家看看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/622884289","repostId":2308078758,"repostType":2,"repost":{"id":"2308078758","kind":"highlight","pubTimestamp":1675308780,"share":"https://www.laohu8.com/m/news/2308078758?lang=&edition=full","pubTime":"2023-02-02 11:33","market":"us","language":"en","title":"Why Editas Medicine Stock Charged Higher in January","url":"https://stock-news.laohu8.com/highlight/detail?id=2308078758","media":"Motley Fool","summary":"The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month.","content":"<html><body><div><h2>What happened</h2><p>Shares of gene-editing company <strong>Editas Medicine</strong> <span>(EDIT<span> 9.82%</span>)</span> rose by a healthy 11.5% over the course of January, according to data provided by S&amp;P Global Market Intelligence. This big monthly gain stemmed from a definitive agreement between Editas and privately held Shoreline Biosciences that was announced on January 19, 2023.</p><p>Per the terms of the agreement, Shoreline will gain access to Editas' proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene-editing technologies via a licensing deal. Furthermore, Shoreline will buy Editas' preclinical gene-edited induced pluripotent stem cell- (iPSC) derived natural killer cell (iNK) programs and related manufacturing technologies. The specific financial terms of the deal weren't disclosed at the time of the announcement, however.</p><h2>So what</h2><p>Earlier in January, Editas announced a reorganization plan centering around the prioritization of its lead blood disorder candidate, EDIT-301. As part of the plan, the biotech also announced a 20% workforce reduction and the culling of some of its earlier-stage assets. In light of those moves, this licensing and asset sale transaction with Shoreline wasn't totally unexpected at the time of its announcement.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"336740\" :show_benchmark_compare=\"false\" amount_change=\"1.02\" average_volume=\"2,084,174\" company_name=\"Editas Medicine\" current_price=\"11.43\" daily_high=\"11.45\" daily_low=\"10.80\" default_period=\"OneMonth\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"21.59\" fifty_two_week_low=\"7.71\" gross_margin=\"-525.90\" logo=\"https://g.foolcdn.com/art/companylogos/mark/EDIT.png\" market_cap=\"$700M\" pe_ratio=\"\" percent_change=\"9.82\" symbol=\"EDIT\" volume=\"956,570\"></app></div><p>As things stand now, Editas ought to have a cash runway that extends through 2025. That's key because EDIT-301 is several years away from producing data that might lead to a regulatory filing. In fact, the novel gene-edited therapy is currently slated to yield midstage sickle cell disease data in late 2025, according to clinicaltrials.gov. Editas, as a result, has a long way to go before it can start funding operations through commercial sales.</p><h2>Now what</h2><p>Is Editas stock worth buying after this double-digit uptick in January?</p><div><div></div></div><p>Although the competitive landscape for treatments for rare blood disorders like sickle cell disease is widely expected to be unfavorable for newcomers in the second half of the decade, Wall Street analysts still think EDIT-301 might be able to hit blockbuster status in this setting. The key will be how the therapy's safety and efficacy results compare to those of other commercially available products.</p><p>So, in a sense, Editas' stock does seem undervalued relative to the company's long-term prospects.</p><p>Having said that, however, there are scores of beaten-down biotech stocks right now, and many of them offer a slew of nearer-term catalysts, meaning we might expect them to grow sooner. Editas, therefore, might be best viewed as an intriguing watch-list candidate for the time being.</p><div></div></div></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Editas Medicine Stock Charged Higher in January</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Editas Medicine Stock Charged Higher in January\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-02 11:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/02/02/why-editas-medicine-stock-charged-higher-in-januar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedShares of gene-editing company Editas Medicine (EDIT 9.82%) rose by a healthy 11.5% over the course of January, according to data provided by S&P Global Market Intelligence. This big ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/02/02/why-editas-medicine-stock-charged-higher-in-januar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F719070%2Fgene-therapy.jpg&op=resize&w=165&h=104","relate_stocks":{"BK4139":"生物科技","EDIT":"Editas Medicine, Inc.","BK4556":"基因编辑"},"source_url":"https://www.fool.com/investing/2023/02/02/why-editas-medicine-stock-charged-higher-in-januar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2308078758","content_text":"What happenedShares of gene-editing company Editas Medicine (EDIT 9.82%) rose by a healthy 11.5% over the course of January, according to data provided by S&P Global Market Intelligence. This big monthly gain stemmed from a definitive agreement between Editas and privately held Shoreline Biosciences that was announced on January 19, 2023.Per the terms of the agreement, Shoreline will gain access to Editas' proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene-editing technologies via a licensing deal. Furthermore, Shoreline will buy Editas' preclinical gene-edited induced pluripotent stem cell- (iPSC) derived natural killer cell (iNK) programs and related manufacturing technologies. The specific financial terms of the deal weren't disclosed at the time of the announcement, however.So whatEarlier in January, Editas announced a reorganization plan centering around the prioritization of its lead blood disorder candidate, EDIT-301. As part of the plan, the biotech also announced a 20% workforce reduction and the culling of some of its earlier-stage assets. In light of those moves, this licensing and asset sale transaction with Shoreline wasn't totally unexpected at the time of its announcement.As things stand now, Editas ought to have a cash runway that extends through 2025. That's key because EDIT-301 is several years away from producing data that might lead to a regulatory filing. In fact, the novel gene-edited therapy is currently slated to yield midstage sickle cell disease data in late 2025, according to clinicaltrials.gov. Editas, as a result, has a long way to go before it can start funding operations through commercial sales.Now whatIs Editas stock worth buying after this double-digit uptick in January?Although the competitive landscape for treatments for rare blood disorders like sickle cell disease is widely expected to be unfavorable for newcomers in the second half of the decade, Wall Street analysts still think EDIT-301 might be able to hit blockbuster status in this setting. The key will be how the therapy's safety and efficacy results compare to those of other commercially available products.So, in a sense, Editas' stock does seem undervalued relative to the company's long-term prospects.Having said that, however, there are scores of beaten-down biotech stocks right now, and many of them offer a slew of nearer-term catalysts, meaning we might expect them to grow sooner. Editas, therefore, might be best viewed as an intriguing watch-list candidate for the time being.","news_type":1},"isVote":1,"tweetType":1,"viewCount":897,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/622884289"}